CircMTO1 suppresses hepatocellular carcinoma progression via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling pathway and epithelial-to-mesenchymal transition

Dandan Li1,2, Jiawei Zhang1,2, Jing Yang1,2, Jie Wang1,2, Runling Zhang1,2, Jinming Li1,2,3✉ and Rui Zhang1,2,3✉

© The Author(s) 2021

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common diagnosed human malignancies worldwide, and its incidence is increasing each year [1]. China alone accounts for approximately 50% of the global liver cancer burden. An estimated 466,100 patients were diagnosed with HCC in China in 2015, of which 422,100 died [2,3]. Resection, transplantation, and ablation are effective for early HCC treatment; however, most patients are diagnosed at advanced stages [4]. Although significant progress has been made in the treatment of liver cancer, HCC incidence and mortality remain high due to tumor recurrence, metastasis, drug resistance, and high adverse side effects, necessitating the identification of new targets for designing more powerful therapeutic approaches.

Recently, circular RNAs (circRNAs), a novel class of non-coding RNAs, have attracted attention [5]. Unlike linear RNAs, circRNAs form covalently closed-loop structures, characterized by stable, abundant, and specific expression in different tissues and cells during development [6]. CircRNAs act as key regulators in a wide range of biological processes, including microRNAs (miRNAs) sponge, RNA binding protein (RBP) sponges, protein/peptide translation templates, gene transcription, and RNA splicing regulators [7]. Mounting evidence shows that circRNAs play vital roles in cancer progression [8–10].

MiRNAs are another type of non-coding RNAs that act mainly via negative regulation of target genes at the post-transcription level by inhibiting protein translation or degrading target mRNAs [11]. MiRNAs can serve as either oncogene or tumor suppressors during the occurrence and development of various cancers [12, 13]. In recent years, a novel regulatory mechanism, called the competing endogenous RNA (ceRNA) hypothesis, has been proposed. CircRNAs have miRNA response elements (MREs) [14] and are known to regulate gene expression by acting as ceRNAs and subsequently counteract miRNA-induced effects on downstream mRNAs by sponging miRNAs, leading to tumorigenesis and development of cancer [15–17].

CircRNA mitochondrial tRNA translation optimization 1 (circMTO1, hsa_circRNA_0007874/hsa_circRNA_104135) originates...
from exons 2 and 3 of the MTO1 gene with a 318 bp splice length [18]. CircMTO1 usually functions as a tumor suppressor and is associated with the progression of multiple tumors [19], including glioblastoma [20], gallbladder cancer [21], lung adenocarcinoma [22], and HCC [23, 24]. CircMTO1 inhibits liver fibrosis in chronic hepatitis B patients via the regulation of miR-17-5p and Smad7 [25]. Silencing circMTO1 facilitates HCC cell proliferation, migration, and invasion and inhibits apoptosis in HCC. Han et al. found that circMTO1 suppressed HCC progression by acting as a sponge of oncogenic miR-9 to promote p21 expression [23]. Similarly, Wang et al. found that circMTO1 was downregulated in HCC tissues and cell lines compared with normal controls. The study also revealed that circMTO1 was a molecular sponge of miR-9-5p, and NOX4 was the target gene of miR-9-5p [24]. These two HCC studies revealed that circMTO1 acted as a miR-9 sponge and can regulate target mRNAs p21 and NOX4, respectively.

However, the circMTO1 signaling pathways involved in HCC progression have yet to be further explored. Interestingly, a study found that circMTO1 inhibited cell proliferation and invasion by regulating the Wnt/β-catenin signaling pathway in colorectal cancer [26]. In addition, circMTO1 suppressed bladder cancer metastasis by sponging miR-221 and inhibited the epithelial-mesenchymal transition (EMT) process. It also inhibited EMT by sponging miR-3200-5p in gastric carcinoma (GC) [27]. Studies have also found that many circRNAs might function as ceRNAs to promote HCC progression by activating the Wnt/β-catenin pathway [28, 29] and EMT [30, 31]. However, whether circMTO1 affects Wnt/β-catenin signaling and EMT in the progression of HCC is not clear.

Moreover, a single circRNA usually contains multiple MREs, so the same circRNA can play a role in HCC by acting as a sponge of multiple miRNAs [32, 33]. For example, cSMARCA5 inhibited the growth and metastasis of HCC mainly by protecting TIMP3 from downregulation by miR-17-3p and miR-181b-5p [33]. We predicted that miR-541-5p may bind to circMTO1 using data from four databases. However, the role of miR-541-5p in HCC development has not yet been reported. The main target mRNA of miR-541-5p involved in liver cancer cell dysfunction requires further investigation. Through database prediction and experimental verification, ZIC1 was shown to be the target of miR-541-5p.

The aims of this study were to explore the function of miR-541-5p in HCC progression and to study whether circMTO1 functions as a suppressor of HCC progression via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling and the EMT process, which may provide a new research direction for targeted HCC therapy.

RESULTS
The expression of has_circ_0007874 (circMTO1) was downregulated in HCC tissue
Three microarrays (GSE97332, GSE94508, and GSE78520) from the GEO database containing 15 HCC patients and 15 normal controls were combined. There were 522 differentially expressed circRNAs, including 257 upregulated and 265 downregulated circRNAs (Table S1). A heatmap showing part of the downregulated genes was shown in Fig. 1A. CircMTO1 expression was lower in the tumor group than in the normal group (P < 0.05) (Fig. 1B, C). Fig 1D showed that circMTO1 is located on chr 6 and the circularization of MTO1 exons 2 and 3 forms circMTO1.

CircMTO1 acted as a miRNA sponge of miR-541-5p in HCC
Studies have shown that circRNAs can function as miRNA sponges that competitively bind to miRNA, thus abrogating the inhibitory effect of miRNAs on downstream target genes [28, 34]. Since circMTO1 is located in the cytoplasm [23], we studied whether it could function as a miRNA sponge, except miR-9, in HCC cells. The ENCORI/starbase, CSCD, circbank, and miRanda databases were used to predict the miRNAs that may bind to circMTO1 (Fig. 2A and Table S2). Three miRNAs: miR-204-5p, miR-211-5p and miR-541-5p, were predicted from the four databases and taken as possible circMTO1 targets. The ENCORI database-predicted sites where miRNA might bind to circMTO1 (Fig. 2B). CircMTO1 is downregulated in HCC as compared to adjacent non-tumor, according to the ceRNA theory, miRNAs are negatively correlated with the expression of circRNAs. Studies have shown that miRNA-204-5p [35, 36] and miRNA-211-5p [37, 38] function as tumor suppressor factors, thus miRNA-541-5p was chosen for the pull-down assay. MiR-9, which has been reported as a target of circMTO1, was selected as a positive control in the pull-down assay. The pull-down assay results showed that the expressions of circMTO1, miR-541-5p, and miR-9 were enriched in HCC cell lines compared to that in controls, and the expression of miR-541-5p was relatively greater than that of miR-9, whereas the linear MTO1 had no enrichment (Fig. 2C, D). A dual-luciferase reporter assay was used to verify whether miR-541-5p could bind to circMTO1. We constructed luciferase reporter vectors for wildtype (WT) circMTO1 and miR-541-5p binding-site mutant (Mut) circMTO1 and co-transfected HEK293T cells with miR-541-5p mimics or NC mimics. Luciferase activity in the WT group co-transfected with miR-541-5p mimics was significantly reduced, while luciferase activity in the Mut group did not change significantly (Fig. 2E). Finally, miRNA-541-5p was verified as the direct target of circMTO1.

Effects of miR-541-5p on proliferation, migration, and invasion of HCC cells in vitro
To better understand the function of miR-541-5p, we performed CCK-8, transwell, and apoptosis assays to investigate the effects of miR-541-5p on proliferation, migration, and invasion of HCC cells. HepG2, SK-Hep1, and SMMC-7721 cells were transfected with miR-541-5p mimics, miR-541-5p inhibitor, or negative control (NC). RT-qPCR was performed to verify transfection efficiency. The results showed that miR-541-5p expression was significantly upregulated after transfecting HepG2, SK-Hep1, and SMMC-7721 cells with miR-541-5p mimics (all P < 0.01), with a thousand-fold increase compared with the control group. MiR-541-5p expression was downregulated in HepG2, SK-Hep1, and SMMC-7721 cells transfected with miR-541-5p inhibitor (all P < 0.05) (Fig. 3A–C). CCK-8 experiments showed that miR-541-5p overexpression promoted cell proliferation of HepG2, SK-Hep1, and SMMC-7721 cells compared with the NC and miR-541-5p knockdown inhibited cell proliferation compared with the NC (Fig. 3D–F). The Transwell assay also showed that migration and invasion of HCC cells were significantly enhanced after overexpression of miR-541-5p, whereas migration and invasion of HCC cells were significantly attenuated after miR-541-5p silencing (Fig. 3G–I). However, apoptosis assay showed that miR-541-5p overexpression suppressed the apoptosis of HepG2, SK-Hep1, and SMMC-7721 cells, and inhibition of miR-541-5p promoted the apoptosis of HepG2, SK-Hep1, and SMMC-7721 cells (all P < 0.05) (Fig. 3J–L).

MiR-541-5p reversed the suppressive effect of circMTO1 in HCC cells
We conducted a rescue experiment to explore the suppression mechanism of circMTO1 in HCC working as a miR-541-5p sponge. HepG2, SK-Hep1, and SMMC-7721 cells were transfected with three circMTO1 siRNAs. Among the three circMTO1 siRNAs, si-1 circMTO1 had the highest silencing efficiency in HepG2, SK-Hep1, and SMMC-7721 cells (Fig. 4A–C). Resultingly, it was selected for further study. The results of the CCK-8 assay showed that circMTO1 silencing enhanced the proliferation of HepG2, SK-Hep1, and SMMC-7721 cells and the proliferation of HCC cells was significantly decreased following miR-541-5p inhibitor transfection (P < 0.05). Transfection with miR-541-5p inhibitor compromised the enhanced proliferation caused by circMTO1 silencing (Fig. 4D–F). Transwell assays demonstrated that miR-541-5p inhibition reversed the promotion of migration and invasion of
HepG2, SK-Hep1, and SMMC-7721 cells caused by circMTO1 knockdown (Fig. 4G–I). Compared with cells transfected with si-circMTO1 alone, co-transfection of HepG2, SK-Hep1, and SMMC-7721 cells with si-circMTO1 and miR-541-5p inhibitor significantly promoted apoptosis (all \( P < 0.05 \)) (Fig. 4J–L). Taken together, these results indicated that circMTO1 suppressed the malignant progression of HCC cells by abolishing the tumorigenic effect of miR-541-5p.

ZIC1 was a direct target of miR-541-5p

Potential miR-541-5p target genes were predicted using miRDB, TargetScan, and ENCORI databases (Table S3), and 239 genes were identified (Fig. 5A and Table S4). According to the ceRNA theory, circMTO1 is positively correlated with the expression of downstream target genes, and the target genes are negatively correlated with the expression of miR-541-5p and the downstream factors function as tumor suppressors as well as circMTO1. We analyzed the 239 genes in the miRNA-mRNA section of the ENCORI database and found nine genes whose expressions were negatively correlated with miR-541-5p. We conducted a literature search for the nine mRNAs in the PubMed database. Among them, ZIC1 and SLC46A3 have been shown to function as tumor suppressors and ZIC1 was found to play an important role in the Wnt/β-catenin pathway and EMT. Therefore, ZIC1 was
chosen as the candidate mRNA (Fig. 5B, C). A luciferase reporter assay was conducted to verify that ZIC1 was the downstream factor of miR-541-5p. MiR-541-5p interacts directly with the 3' UTR of mRNA, thus we constructed Wt ZIC1 3' UTR and miR-541-5p binding-site Mut luciferase reporter plasmids. The Wt and Mut reporter vectors were co-transfected into cells together with the miR-541-5p mimics. The results showed that the relative luciferase activity of miR-541-5p mimics and the ZIC1 Wt group was lower (*P < 0.05), while the luciferase activity of the Mut group did not change significantly (Fig. 5D). Thus, ZIC1 was confirmed as a downstream factor of miR-541-5p. In addition, overexpression of miR-541-5p significantly decreased the expression of ZIC1 mRNA and protein, whereas downregulation of miR-541-5p increased ZIC1 expression in SMMC-7721 and HepG2 cells (Fig. 5E, F). Moreover, ZIC1 levels decreased when SMMC-7721 and HepG2 cells were transfected with si-circMTO1. Compared with the circMTO1 silencing group, HCC lines co-transfected with si-circMTO1 and miR-541-5p inhibitor showed higher levels of ZIC1 mRNA and protein (Fig. 5G, H).

CircMTO1 inhibited the malignant progression of HCC by miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling and EMT

ZIC1 was modulated to determine whether it affected Wnt/β-catenin signaling and EMT downstream factors. Among the three ZIC1 siRNAs, si-3 ZIC1 had the highest silencing efficiency in HepG2 and SMMC-7721 cells (Fig. 6A), and therefore, it was selected for further study. ZIC1 expression was lower after transfection with si-ZIC1 (Fig. 6A, C) and was significantly upregulated after the transfection of HepG2 and SMMC-7721 cells with the ZIC1-overexpressing plasmid (OE-ZIC1) compared with that in the vector group (Fig. 6B–D). ZIC1 silencing significantly upregulated the expression of β-catenin, cyclin D1, and c-myc, which are key factors in the Wnt/β-catenin signaling pathway, and N-cadherin, Vimentin, and MMP2 expression, which are key factors in EMT; however, the level of E-cadherin, which is the key biomarker in EMT, decreased (Fig. 6E, F). The key factors of the OE-ZIC1 group exhibited the opposite trend (Fig. 6G, H). The next step was to clarify whether circMTO1 inhibited the malignant progression of HCC through the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling and EMT. When SMMC-7721 and HepG2 cells were transfected with miR-541-5p mimics or si-circMTO1, the expression of downstream ZIC1 regulators, β-catenin, cyclin D1, c-myc, N-cadherin, Vimentin, and MMP2 were upregulated; however, the level of E-cadherin was downregulated (Fig. 7). The downregulation of miR-541-5p produced the opposite results (Fig. 7A–C). And the expression of downstream ZIC1 regulators, β-catenin, cyclin D1, c-myc, N-cadherin, Vimentin, and MMP2 were significantly decreased after co-transfection with the miR-541-5p inhibitor and si-circMTO1 compared with transfection with si-circMTO1 alone. However, the expression of E-cadherin increased (Fig. 7D–F).
The circMTO1/miR-541-5p/ZIC1 axis inhibited tumor growth in vivo and was a potential therapeutic target. To investigate whether the circMTO1/miR-541-5p/ZIC1 axis can serve as a promising therapeutic target, we constructed xenograft tumor models of nude mice by subcutaneously injecting them with SMMC-7721 cells. After intratumoral injection of cholesterol-conjugated circMTO1 siRNAs, tumor growth was significantly accelerated and the tumor weight was also significantly greater than in the PBS and NC groups (Fig. 8A–C). After intratumoral injection of cholesterol-conjugated miR-541-5p inhibitor, tumor growth was inhibited and tumor weight was less than in the PBS and NC groups. This reversed the promoting effect of circMTO1 silencing on tumor growth (Fig. 8A–C).

Total RNA extracted from xenograft tumors and RT-qPCR was used to measure the expression of circMTO1, miR-541-5p, and ZIC1. The results showed decreased circMTO1 and ZIC1 expression, while miR-541-5p expression was increased in tumors with circMTO1 silencing (Fig. 8D–F). The expression of miR-541-5p was lower than that in the PBS and NC groups after miR-541-5p knockdown, while the expression of ZIC1 was higher than that in the PBS and NC groups (Fig. 8E, F). Furthermore, H&E staining demonstrated that circMTO1 knockdown increased the nuclear volume and varied the size, and the frequency of nuclear division was also higher than in the other groups (Fig. 8G). IHC staining demonstrated that the expression of ZIC1 and the EMT marker E-cadherin were downregulated in si-circMTO1 xenograft tumors (Fig. 8H). In addition, when the expression of circMTO1 decreased, the Wnt/β-catenin signaling markers, β-catenin, c-myc, cyclin D1 and the
EMT markers N-cadherin, Vimentin, and MMP2 were higher than those in the PBS and NC groups, while the Wnt/β-catenin signaling markers β-catenin, c-myc, cyclin D1, and the EMT markers N-cadherin, Vimentin, and MMP2 were lower than those in the PBS and NC groups with a miR-541-5p knockdown. These data confirmed that circMTO1 suppressed the malignant progression of HCC in vivo via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling and EMT.

**DISCUSSION**

As novel gene regulators, circRNAs exert their roles at the transcriptional or post-transcriptional levels to regulate downstream factors [39]. Increasing evidence suggests that circRNAs can be differently expressed in tumor tissues and can participate in HCC progression [31, 40, 41], working as biomarkers for HCC therapeutic targets or prognosis [42]. A growing body of evidence shows that circMTO1 can function as a suppressor in multiple cancers [43, 44]. Han et al showed that decreased circMTO1 expression was correlated with poor prognosis in a cohort of 116 HCC patients [23]. Therefore, in this study, we did not explore the prognostic function of circMTO1, and data from loss-of-function experiments have indicated that circMTO1 silencing can promote proliferation, migration, and invasion of HCC cells while inhibiting apoptosis. Instead, we focused on identifying the downregulated miRNA of circMTO1 to explore promising...
therapeutic targets. In this study, we elucidated a new mechanism through which circMTO1 suppresses HCC progression via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling and EMT. MiRNA-541-5p was identified as a direct target of circMTO1. To the best of our knowledge, this study is the first to explore the effect of miR-541-5p on HCC progression. Here, three different cell lines (HepG2, SMMC-7721, and SK-Hep1) were used to improve the robustness of the study and the results were consistent, revealing that miR-541-5p promoted proliferation, migration, and invasion of HCC cells and inhibited apoptosis in vitro. Further, a rescue experiment was carried out to explore whether circMTO1 suppresses HCC by acting as a miR-541-5p sponge. The rescue experiments revealed that in the circMTO1 and miR-541-5p inhibitor co-transfected system, miR-541-5p inhibitor attenuated the effect of downregulated circMTO1 on cell proliferation, migration, invasion, and apoptosis, suggesting that circMTO1 can regulate miR-541-5p and affect HCC progression.

As previously mentioned, miRNAs are also considered a class of non-coding RNAs and are 22–25 nucleotides long [45]. They exert their functions by targeting 3’UTRs of mRNA post-transcriptionally and repressing gene expression [46]. In our study, the dual-luciferase reporter assay identified ZIC1 as the direct target of miR-541-5p. ZIC1 finger of cerebellum 1 (ZIC1) is located on chromosome 3q25.1, belongs to the ZIC family, which encodes a...
zinc-finger transcription factor and serves as a transcriptional cofactor [47]. Ge et al. demonstrated that lower expression of ZIC1 was correlated with increased lymph node metastasis and poor outcome in GC patients. Mechanistically, ZIC1 can downregulate Wnt targets including c-Myc and cyclin D1 by attenuating the \( \beta \)-catenin/ transcription factor 4 (TCF4) complex and modulating the EMT process in GC cells [48]. EMT also contributes to the progression of the disease, including organ fibrosis and cancer, and has been recognized as a key step in the progression of cancer metastasis [49]. Furthermore, Wnt/\( \beta \)-catenin signaling has a major impact on EMT. Nuclear \( \beta \)-catenin binds to members of the TCF/LEF family of transcription factors to promote EMT [49]. ZIC1 is an essential regulator of the Wnt/\( \beta \)-catenin and EMT signaling networks. Results from RT-qPCR and western blot (Fig. 5G, H) revealed that ZIC1 expression can be regulated by circMTO1 through miR-541-5p. Moreover, circMTO1 competitively bound to miR-541-5p and relieved the inhibitory effect of miR-541-5p on ZIC1 expression, thereby upregulating ZIC1 expression. CircMTO1 silencing increased the expression of Wnt/\( \beta \)-catenin downstream markers such as \( \beta \)-catenin, cyclin D1, c-myc, and mesenchymal markers such as N-cadherin, vimentin, and MMP2, while the epithelial marker, E-cadherin, was downregulated. MiR-541-5p knockdown had the opposite effect and reversed the effect of circMTO1 silencing on the expression of downstream ZIC1 regulator, indicating that the circMTO1/miR-541-5p/ZIC1 axis suppressed proliferation, migration, and invasion by regulating the Wnt/\( \beta \)-catenin pathway and EMT.

In further in vivo studies, we verified the regulatory relationship of the circMTO1/miR-541-5p/ZIC1 axis. CeRNAs can compete with mRNAs, when miRNAs combine with ceRNAs, miRNAs and circRNAs expression levels are usually reversed. The miRNAs transcription level regulated by miRNAs are consistent with the expression level of circRNAs. Our in vivo results proved that miR-541-5p increased when circMTO1 was knocked down, while the expression of ZIC1 decreased (Fig. 8E, F). MiRNAs are known as non-coding RNAs, and they can be used as biomarkers for HCC treatment [50, 51]. In our in vivo study, tumor growth was inhibited after intratumoral injection of cholesterol-conjugated miR-541-5p inhibitor but increased by intratumoral injection of cholesterol-conjugated circMTO1 siRNA, indicating that the in vivo intervention of circMTO1/miR-541-5p/ZIC1 axis could be a potential target in HCC targeted therapy. In order to gain a deeper understanding of the role of circMTO1, further investigation of its biogenesis mediated by pre-mRNA
splicing needs to be explored. We searched circinteractome (https://circinteractome.nia.nih.gov/index.html), three RBPs: DGCR8, eukaryotic initiation factor 4A3 (EIF4A3), and U2AF65 were predicted to have putative binding sites matching the flanking regions of circMTO1. A previous study showed that the sequence located upstream of circMMP9, which contained EIF4A3 binding sites, was important for the interaction between EIF4A3 and MMP9 mRNA. EIF4A3 bound to the MMP9 mRNA transcript, inducing circMMP9 cyclization and increasing circMMP9 expression in glioblastoma multiforme [52]. Moreover, EIF4A3 was found to be a core component of the exon junction complex and played an essential role in pre-mRNA splicing. The RT-qPCR assay showed that overexpression of EIF4A3 facilitated the expression of circSEPT9, while EIF4A3 knockdown inhibited circSEPT9 expression in triple-negative breast cancer cells [53]. Exploring whether EIF4A3 with an effect on circMTO1 biogenesis is of great significance and should be pursued in future studies to develop non-invasive circMTO1 detection methods for HCC that can be used in clinical applications.

In summary, our study showed that miR-541-5p promoted the proliferation, migration, and invasion and inhibited apoptosis of HCC cells. Functionally and mechanistically, circMTO1 competitively bound miR-541-5p and eliminated its inhibitory effect on ZIC1, thereby suppressing HCC cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signaling pathway and EMT both in vitro and in vivo. These findings provide new insights...
into the occurrence and progression of HCC and indicate that the circMTO1/miR-541-5p/ZIC1 axis may serve as a potential therapeutic target for the treatment of HCC.

MATERIALS AND METHODS

Microarray data information from the Gene Expression Omnibus (GEO) database for the screening study

The gene expression profiles from GSE97332 (including seven adjacent nontumorous samples and seven HCC samples; platform: GPL19978), GSE94508 (including five adjacent nontumorous samples and five HCC samples; platform: GPL19978), GSE78520 (including three liver cancer tissue and three normal liver tissue; platform: GPL19978) were obtained from the GEO database (http://www.ncbi.nlm.nih.gov/geo/). We combined the three microarrays, including 15 liver cancer patients and 15 controls to screen the differential expression of circRNAs. CircRNAs exhibiting fold changes (FCs) ≥2.0 with P values <0.05 were considered differentially expressed.

Cell lines and cultivate

Three HCC cell lines (SK-hep1, SMMC-7721, and HepG2) and HEK293T cells were purchased from Shanghai Xinyu Biological Technology Co., Ltd. SMMC-7721 cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin. HepG2 cells and HEK293T cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) supplemented as above.
SK-Hep1 cells was cultured in MEM (Gibco, Carlsbad, CA, USA) supplemented as above. All cell lines were cultured at 37 °C under 5% CO₂. The medium was replaced every 2 days and the cells in the log phase were used for the experiments.

**RNA extraction and quality control**

Total RNA was extracted with Trizol reagent (Invitrogen, USA) according to the manufacturer's instructions. A Nanodrop ND-2000 instrument (Thermo Fisher Scientific, USA) was used to evaluate the quality of the RNA samples.

**Reverse transcription real-time quantitative PCR (RT-qPCR)**

Total RNA was isolated and 2 μg of total RNA was used in reverse transcription with PrimeScript RT Reagent Kit (Takara, Dalian, China) according to the manufacturer's protocol. RT-qPCR was conducted on the ABI Prism 7500 system (Applied Biosystems, CA, USA) with SYBR Green Premix Ex Taq (Takara, Dalian, China). GAPDH was used as an internal control for circRNA and mRNA, while U6 was used for miRNA. The relative expression of genes was calculated using the 2⁻ΔΔCT method. The Primers used in the experiments were purchased from Sangon Biotech (Shanghai, China) Co., Ltd. and presented in Table S5.

**Plasmid construction and cell transfection**

The construction of plasmids that overexpressed circMTO1 and ZIC1 (OE-ZIC1) were conducted by Geneseeed Biotech (Guangzhou, China) Co., Ltd. Briefly, the full-length human circMTO1 was amplified and inserted into the overexpression vector pLCS5-circ. The ZIC1 expression plasmid was constructed by cloning the full-length ZIC1 open reading frame into the pcDNA3.1(−) vector. The sequence and orientation of the inserts were confirmed using DNA sequencing. The empty pcDNA3.1(−) vector was used as a negative control. For luciferase reporter plasmids, the circMTO1 sequences of wildtype and mutant type that bind to the miR-541-5p were cloned into the pmirGLO vector (Promega, USA). Cell transfections were conducted with Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer's protocols.

**Small interfering RNA (siRNA), miRNA mimics, and inhibitor**

The sequences of circMTO1 siRNAs (siRNA-1, siRNA-2, and siRNA-3 circMTO1), ZIC1 siRNAs (siRNA-1, siRNA-2, and siRNA-3 ZIC1), negative control (NC), miR-541-5p mimics, and miR-541-5p inhibitor were synthesized by GenePharma (Shanghai, China) and are presented in Table S6. CircMTO1 siRNA stable oligonucleotides (modified by cholesteryl, cholesterol-conjugated 2′-OMe-modified, chemically modified single-stranded RNA molecule, miR-541-5p inhibitor, and cholesterol-conjugated NC in vivo experiment were synthesized by GenePharma (Shanghai, China).

**RNA pull-down assay**

RNA pull-down experiments were performed with RNA Antisense Purification (RAP) Kit (BersinBio, China). Briefly, 4 × 10⁵ HepG2 and SMMC-7721 cells, overexpressed circMTO1, were collected, respectively. And the cell pellets were homogenized, and the appropriate amount of oligo probes were designed. The procedures: cross-link cells and cell pellet, homogenization, probe preparation (antisense oligo probes were designed using the following parameters: a. number of probes = 1 probe/100 nucleotides of RNA; b. target GC% = 45%; c. oligonucleotide length = 20; d. spacing length = 60–80). circMTO1 probes: probe 1: TGACATCTGACCCAAAACAA; probe 2: GATGCGGAGAACACAGCCCAT; probe 3: ATCAATGTCAGCTCCAGAC; probe 4: AAG ATCTTCTACAGCCTCCT. Negative probes: probe 1: CAAACGGCGGATTGACCTCAGTAAAGGATGTGCGTGGGCGGATCGTAAC; probe 2: CAC CACAAGACCCGGAGAGGCGGAGGACGGTATCGTGA; probe 3: CACAACTGCGGATCCAGGTCGCGCGAGTCGACCCCTA; probe 4: GATGCGGAGAACACAGCCCAT. The RNA samples were synthesized and subcloned into luciferase reporter vector pmirGLO, which were transfected into HEK293T cell combination with miR-541-5p mimics or NC mimics. The relative luciferase activity was determined by the Dual-Luciferase® Reporter 1000 Assay System (Promega, USA).

**CCK-8 assay**

After 24 h transfection, cells were digested, and seeded into 96-well plates (4 × 10³ cells/100 μL) with 100 μL CCK-8 reagent. After 4 h of incubation, the absorbance of the solution was measured at 450 nm using a Multiskan FC detection system (Thermo Fisher, USA).

**Apopotosis assays**

Briefly, cells were digested with EDTA-free trypsin and washed with ice-cold PBS. Apoptosis assays were executed using double staining with fluorescein APC-conjugated Annexin V and propidium iodide (PI). Next, the percentages of cells were analyzed on a flow cytometer (BD Accuri C6 Plus, USA). The software Flow Jo was used to analyze the data and draw the pictures.

**Transwell cell migration and invasion assays**

The migration/invasion assay was performed using Transwell plates without/with Matrigel gel in the top chambers. HepG2, SK-Hep1, and SMMC-7721 cells were transfected with NC, miR-541-5p mimics, miR-541-5p inhibitor, and/or si-circMTO1 and incubated in transwell plates for 24 h, digested with 0.25% trypsin, suspended in serum-free medium, and counted. Then, 200 μl of transfected cells were plated in the upper chamber, and 600 μl of DMEM containing 10% FBS was added to the lower chamber. After 24 h of incubation, the upper chamber was washed twice with PBS. The cells on the upper surface were discarded with a cotton swab and the cells left were fixed with anhydrous methanol for 30 min and stained with 0.1% crystal violet for 30 min. The cells that migrated through an 8-μM pore membrane or invaded through the Matrigel-coated membrane were stained and counted under a microscope.

**Western blot analysis**

Cells and tissues were added with an appropriate amount of RIPA (PMSF) buffer. Then, the total protein was extracted by centrifugation, the total protein concentration was determined using the BCA method. Equal amounts of total protein (20 μg) were separated by 8% SDS-PAGE and transferred onto PVDF membranes (Millipore, Billerica, MA), followed by 5% skim milk for 1 h at room temperature to block nonspecific bindings. The membranes were incubated with the following primary antibodies overnight at 4 °C and washed five times with 1×TBST for 5 min each time: ZIC1 (Abcam, ab134951), β-catenin (Abcam, ab25272), c-myc (proteintech, 67447-1-lg), cyclin D1 (ab134175), E-cadherin (Abcam, ab40772), N-cadherin (ab67011), Vimentin (Abcam, ab29547), MMP2 (proteintech, 66366-1-lg). β-actin (CWBio, CW0096M) was used as the internal control. The membranes were then incubated with secondary antibodies (HRP-labeled goat anti-rabbit IgG or goat anti-mouse IgG) at room temperature for 1 h and washed five times with 1×TBST for 5 min each time. Bands were detected by a chemiluminescence imaging system (SageCreation Science, Beijing, China) with SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific, USA).

**Xenograft tumorigenesis**

25 SPF-grade male BALB/C nude mice (6–8 weeks) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) with an average weight of 15.4 g (ranging from 14.7 to 16.1 g). All nude mice were housed under SPF conditions (TECNIPLAST S.p.A., Italy) and randomly divided into five groups. A total of 5 × 10⁶ SMMC-7721 cells were suspended in 100 μL PBS and subcutaneously injected into the right flank of each mouse. Once the tumor volume reached 100–200 mm³, intratumoral injections of PBS, cholesterol-conjugated NC, cholesterol-conjugated si-circMTO1, cholesterol-conjugated si-circMTO1 + cholesterol-conjugated 2′-OMe-modified miR-541-5p inhibitor, and cholesterol-conjugated si-circMTO1 + cholesterol-conjugated 2′-OMe-modified miR-541-5p inhibitor were administered a total of five times, three days apart. Tumor volume was calculated every three days, which was calculated as follows: V (volume) = (length × width²)/2. Tumor weight was weighted at the end-point of the experiment. After
24 days, the mice were killed and the tumors were dissected and processed for histological analysis.

**Immunohistochemistry (IHC) staining**

In brief, paraffin sections of xenograft tumor tissues were cut into 4-μm sections. Sections underwent dewaxing, rehydration, antigen retrieval, and blocking, and then were incubated with antibodies against ZIC1, β-catenin, c-myc, cyclin D1, E-cadherin, N-cadherin, Vimentin, MMP2 for 20 min at room temperature in a moist chamber, and washed five times with PBS. Sections were incubated with HRP-conjugated secondary antibody for 20 min at room temperature, washed five times with PBS, and then stained with DAB and hematoxylin. Next, sections were dehydrated and mounted with coverslips.

**H&E staining**

Tissue samples were fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 4-μm thick sections. H&E staining was performed to observe the histopathological features.

**Statistical analysis**

The Kolmogorov–Smirnov test was used to estimate the distribution of the data. Normally distributed continuous variables are presented as mean ± standard deviation values. Statistical significance was determined by a one-way ANOVA test or a Student’s t-test. Data were processed with GraphPad (San Diego, California, USA). All P values presented are two-tailed, and values of P < 0.05 were considered statistically significant. Analyses were performed using the SPSS 20.0 software (Armonk, NY, USA). The free online tool Venny 2.1 was used (https://bioinfogp.cnb.csic.es/tools/venny/).

**DATA AVAILABILITY**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
4. Sun HZ, Song YL, Wang XY. Effects of different anesthetic methods on cellular immune and neuroendocrine functions in patients with hepatocellular carcinoma before and after surgery. J Clin Lab Anal. 2016;30:1175–82.
5. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381–8.
6. Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32:309–16.
7. Bach OH, Lee SK, Sood AK. Circular RNAs in cancer. Mol Ther Nucleic Acids. 2019;16:118–29.
8. Zhang X, Yao J, Shi H, Gao B, Zhou H, Zhang Y, et al. Hsa_circ_0026628 promotes the development of colorectal cancer by targeting TP53 to activate the Wnt/β-catenin pathway. Cell Death Dis. 2021;12:802.
9. Liu H, Hu G, Wang Z, Liu Q, Zhang J, Chen Y, et al. circPTCH1 promotes invasion and metastasis in renal cell carcinoma via regulating miR-485-5p/MMP2 axis. Theranostics 2020;10:10791–807.
10. Huang Q, Guo H, Wang S, Ma Y, Chen H, Li H, et al. A novel circular RNA, circPDX1, promotes lung adenocarcinoma progression by interacting with IGF2BP1. Cell Death Dis. 2020;11:1031.
11. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–55.
12. Guo ZZ, Ma ZJ, He YZ, Jiang W, Xia Y, Pan CF, et al. miR-550a-5p functions as a tumor suppressor by targeting LIMD1 in lung adenocarcinoma. Front Oncol. 2020:10:570733.
13. Liang Y, Li S, Tang L. MicroRNA 320, an anti-oncogene target miRNA for cancer therapy. Biomedicines. 2021;9:591.
14. Jeck WR. Sharpless NE. Detecting and characterizing circular RNAs. Nat. Biotechnol. 2014;32:453–61.
15. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495:384–8.
16. Zhao X, Cai Y, Xu J. Circular RNAs: biogenesis, mechanism, and function in human cancers. Int. J. Mol. Sci. 2019;20.
ACKNOWLEDGEMENTS

We sincerely appreciate all lab members.

AUTHOR CONTRIBUTIONS

J.L. and D.L. contributed to the experiment design. D.L., J.W. and R.-L.Z. contributed to the experiment implementation. D.L., J.W. and J.Y., contributed to manuscript draft and data analysis. R.Z. and J.L. reviewed and edited the manuscript. All the authors read, revised, and approved the final manuscript.

FUNDING

The present study was funded by the National Natural Science Foundation of China (grant no. 81772273; www.nsfc.gov.cn).

CONFLICT OF INTEREST

The authors declare no competing interests.

ETHICS APPROVAL

All experimental procedures involving animals were approved by the Ethics Committee of the National Center for Clinical Laboratories, Beijing Hospital.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04464-3.

Correspondence and requests for materials should be addressed to Jinming Li or Rui Zhang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021